Zur Kurzanzeige

2013-03-05Zeitschriftenartikel DOI: 10.1186/1743-422X-10-72
Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
dc.contributor.authorRoss, Stefan
dc.contributor.authorStambouli, Oumaima
dc.contributor.authorGrüner, Nico
dc.contributor.authorMarcus, Ulrich
dc.contributor.authorCai, Wei
dc.contributor.authorZhang, Weidong
dc.contributor.authorZimmermann, Ruth
dc.contributor.authorRoggendorf, Michael
dc.date.accessioned2018-05-07T16:17:03Z
dc.date.available2018-05-07T16:17:03Z
dc.date.created2013-03-19
dc.date.issued2013-03-05none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/re5h45pLllGnk/PDF/28tpEGhT5YVY.pdf
dc.identifier.urihttp://edoc.rki.de/176904/1423
dc.description.abstractBackground: Nowadays, dried blood spots (DBS) are primarily used to obtain diagnostic access to risk collectives such as intravenous drug users, who are prone to infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Before DBS analyses can be used in this diagnostic context, however, a comprehensive evaluation of its performance characteristics must be conducted. To the best of our knowledge, the current study presents for the first time such essential data for the Abbott ARCHITECT system, which is currently the worldwide leading platform in this field of infection diagnostics. Methods: The investigation comprised 1,762 paired serum/DBS samples and a total of 3,524 determinations with the Abbott ARCHITECT HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24-antigen/anti-HIV 1/2 assays as well as with the artus HBV LC PCR and VERSANT HCV RNA qualitative (TMA) tests. Results: In the context of DBS testing, a specificity of 100% was recorded for the seven serological and molecular biological assays. The analytical sensitivity of HBsAg, anti-HBc, anti-HBs, anti-HCV, HIV-1-p24-antigen/anti-HIV 1/2, HBV DNA, and HCV RNA detections in DBS eluates was 98.6%, 97.1%, 97.5%, 97.8%, 100%, 93%, and 100%, respectively. Discussion/conclusions: The results obtained indicate that it is today possible to reliably detect HBsAg, anti-HBc, anti-HBs, anti-HCV and HIV-1-p24 antigen/anti-HIV 1/2 with state-of-the-art analytical systems such as the Abbott ARCHITECT in DBS eluates even when a comparatively high elution volume of 1,000 μl is used. They also provide evidence for the inherent analytical limits of DBS testing, which primarily concern the anti-HBc/anti-HBs system for individuals with HIV infections and nucleic acid tests with relatively low analytical sensitivity.eng
dc.language.isoeng
dc.publisherRobert Koch-Institut, Infektionsepidemiologie
dc.subjectHepatitis B virus infectioneng
dc.subjectHepatitis C virus infectioneng
dc.subjectHuman immunodeficiency virus infectioneng
dc.subjectDried blood spotseng
dc.subjectIntravenous drug userseng
dc.subjectSerological testingeng
dc.subjectMolecular testingeng
dc.subjectReal-time PCReng
dc.subjectTranscription-mediated amplificationeng
dc.subject.ddc610 Medizin
dc.titleDetection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10029648
dc.identifier.doi10.1186/1743-422X-10-72
dc.identifier.doihttp://dx.doi.org/10.25646/1348
local.edoc.container-titleVirology Journal
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://www.virologyj.com/content/10/1/72
local.edoc.container-publisher-nameBioMedCentral
local.edoc.container-volume10
local.edoc.container-issue72
local.edoc.container-year2013

Zur Kurzanzeige